Brad Loncar stopped by last week to chat with our CEO Paul Bolno about our positive SELECT-HD data and what they mean for Wave. Watch the full BiotechTV interview: https://lnkd.in/g6RbwKn8
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program. He highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest of the year from Wave's DMD, AATD, and weight loss programs. Full video: https://lnkd.in/g6RbwKn8 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent